Brown Rudnick, an international law firm representing clients around the world, has advised EDX Medical Group on its share-for-share acquisition of Oxford-based Hutano Diagnostics Ltd. The deal was originally announced on September 27, but Brown Rudnick’s involvement in the transaction wasn’t announced until October 10.
Hutano Diagnostics is a start-up developing a diagnostic and surveillance platform for diseases caused by emerging and dangerous pathogens that cause recurring epidemics in Africa. The company is currently developing an Ebola diagnostic and surveillance platform.
Founded in 2022, EDX Medical is a developer of digital diagnostic products and services for the personalized treatment of cancer, heart disease and infectious diseases.
The acquisition will enable EDX Medical to expand its point-of-care testing capabilities with a range of tests, which will be used to identify early signs of cancer, infections and cardio-vascular conditions, and can be carried out by health professionals at the point-of-care. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 105th Laboratories, MRI and Dialysis transaction of 2023, and 54th in the diagnostic specialty.
